Your browser is no longer supported. Please, upgrade your browser.
GLPG Galapagos NV daily Stock Chart
Galapagos NV
Index- P/E- EPS (ttm)-1.69 Insider Own- Shs Outstand54.30M Perf Week23.44%
Market Cap9.89B Forward P/E- EPS next Y-2.87 Insider Trans- Shs Float41.30M Perf Month-15.84%
Income- PEG- EPS next Q-0.64 Inst Own11.78% Short Float3.49% Perf Quarter-12.93%
Sales- P/S- EPS this Y-166.30% Inst Trans- Short Ratio6.57 Perf Half Y17.15%
Book/sh25.49 P/B7.14 EPS next Y-73.90% ROA- Target Price225.52 Perf Year89.47%
Cash/sh- P/C- EPS next 5Y46.40% ROE- 52W Range94.75 - 274.03 Perf YTD-11.94%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-33.53% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low92.23% ATR15.33
Employees- Current Ratio- Sales Q/Q27.20% Oper. Margin- RSI (14)47.73 Volatility5.53% 7.72%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.63 Prev Close187.49
ShortableYes LT Debt/Eq- EarningsApr 24 AMC Payout- Avg Volume218.99K Price182.14
Recom2.60 SMA200.18% SMA50-16.35% SMA200-0.81% Volume356,064 Change-2.85%
Mar-18-20Upgrade RBC Capital Mkts Underperform → Sector Perform $175 → $157
Feb-25-20Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-24-20Downgrade BofA/Merrill Neutral → Underperform
Feb-20-20Downgrade RBC Capital Mkts Sector Perform → Underperform $175
Jan-06-20Downgrade JP Morgan Overweight → Neutral
Dec-18-19Downgrade Citigroup Buy → Neutral
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $174 → $169
Dec-02-19Initiated BofA/Merrill Neutral
Sep-09-19Resumed Morgan Stanley Overweight
Jul-31-19Upgrade UBS Neutral → Buy
Jul-29-19Downgrade Jefferies Buy → Hold
Jul-15-19Reiterated H.C. Wainwright Buy $150 → $205
Jul-10-19Resumed Credit Suisse Outperform
Mar-29-19Reiterated H.C. Wainwright Buy $136 → $150
Mar-28-19Initiated H.C. Wainwright Buy $136
Feb-22-19Initiated SVB Leerink Outperform
Dec-19-18Initiated Cantor Fitzgerald Overweight
Dec-13-18Upgrade Credit Suisse Neutral → Outperform
Nov-15-18Initiated Raymond James Strong Buy
Mar-18-20 02:29PM  Top Biotech Stocks for Q2 2020 Investopedia -5.36%
Mar-17-20 02:38PM  Hedge Funds Were Buying Galapagos NV (GLPG) Before The Coronavirus Insider Monkey
Mar-06-20 06:10AM  5 Biotech Stocks to Buy for a Strong Growth Prognosis InvestorPlace
Feb-05-20 09:21AM  Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat Zacks
09:15AM  Vertex (VRTX) Hits 52-Week High, Can the Run Continue? Zacks
Jan-16-20 10:34AM  Big Pharma Remains Accused of Keeping Prices High. That Wont Change Soon.
07:22AM  The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics Benzinga
Jan-15-20 08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga
Jan-06-20 10:21AM  Buy Sanofi Stock Because Its Undervalued, J.P. Morgan Says
Jan-03-20 05:43PM  2020 Preview: The year ahead in Bay Area biotech and health American City Business Journals
Dec-26-19 10:26AM  Gilead (GILD) Partners With Eisai for RA Candidate in Japan Zacks
Dec-20-19 08:27AM  Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib Zacks
Dec-13-19 04:06PM  Is Galapagos NV (GLPG) A Good Stock To Buy? Insider Monkey
Dec-03-19 03:42PM  Hedge Funds Love Vereit Inc (VER) Way More Than These 4 Stocks Insider Monkey
Dec-02-19 02:57PM  7 Exciting Biotech Stocks to Buy Now InvestorPlace
Nov-13-19 07:34AM  Is Galapagos NV's (AMS:GLPG) CEO Pay Justified? Simply Wall St.
Nov-09-19 04:30PM  New Data on Filgotinib in Rheumatoid Arthritis (RA) Demonstrate Durable Efficacy and Safety Profile Business Wire
Oct-31-19 04:01PM  Gilead and Galapagos to Present New Data on Filgotinib at 2019 ACR/ARP Annual Meeting Business Wire
Oct-25-19 10:36AM  Gilead's (GILD) Earnings Miss Estimates in Q3, Sales Beat Zacks
Oct-23-19 10:06AM  Were Hedge Funds Right About Overlooking Galapagos NV (GLPG)? Insider Monkey
Oct-18-19 11:22AM  New Gilead CFO: Let's Make a Deal
11:17AM  Will Strong HIV Sales Drive Gilead's (GILD) Q3 Earnings? Zacks
Oct-16-19 04:00AM  HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Galapagos NV Business Wire
Oct-11-19 09:19AM  Gilead-Galapagos Report Efficacy & Safety Results on RA Drug Zacks
08:14AM  The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout Benzinga
Oct-10-19 06:00PM  Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis Business Wire
Oct-09-19 11:10AM  Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan Zacks
Sep-26-19 12:38PM  Foreign Firms Recognized as Hottest Biotechs
Sep-03-19 05:46PM  Top-Performing Biotech ETFs YTD Zacks
Aug-29-19 09:00AM  Galapagos NV (GLPG) Upgraded to Buy: Here's What You Should Know Zacks
Aug-28-19 10:34AM  Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More Zacks
Aug-26-19 08:28AM  Gilead & Galapagos Close Research & Development Agreement Zacks
Aug-23-19 04:01PM  Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration Business Wire
Aug-16-19 09:19AM  Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe Zacks
Aug-15-19 04:01PM  European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis Business Wire
Aug-05-19 01:08PM  Here's Why Galapagos NV Rose 34.5% in July Motley Fool
Jul-31-19 09:55AM  Gilead (GILD) Q2 Earnings & Sales Beat, Sales Guidance Raised Zacks
Jul-29-19 04:43PM  Marijuana Stock Cann('t)Trust, and What's Behind Gilead's Latest Megadeal Motley Fool
Jul-26-19 06:23PM  Galapagos NV (GLPG) Q2 2019 Earnings Call Transcript Motley Fool
11:50AM  Will Strong HIV Sales Drive Gilead's (GILD) Q2 Earnings? Zacks
10:11AM  Top Ranked Momentum Stocks to Buy for July 26th Zacks
Jul-22-19 10:37AM  Galapagos NV (GLPG) Shares March Higher, Can It Continue? Zacks
Jul-18-19 04:02PM  Transparency notification GlobeNewswire
Jul-17-19 10:06AM  Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks
07:15AM  Gilead's Galapagos Deal: What It Means for Investors Motley Fool
Jul-16-19 09:50AM  Company News for Jul 16, 2019 Zacks
Jul-15-19 07:40PM  Gilead Sciences, Inc. -- Moody's: Gilead's collaboration with Galapagos credit positive Moody's +17.16%
05:34PM  Wall Street Mixed on Monday
04:50PM  What Happened in the Stock Market Today Motley Fool
04:48PM  Nasdaq Today: Bitcoin & Libra; Whats Broadcom Doing? InvestorPlace
04:26PM  Stocks eke out another round of records as investors brace for 2nd-quarter earnings MarketWatch
02:32PM  Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake InvestorPlace
10:22AM  Gilead Risks Regrets on Pricey Galapagos Partnership Bloomberg
10:01AM  Galapagos Notches $3.95B Upfront Investment From Gilead Benzinga
09:57AM  How Gilead's $5.1 billion deal could steal a page from Genentech-Roche hookup American City Business Journals
09:26AM  Gilead Sciences Says No to Megamerger, Signs a Deal to Collaborate With Galapagos
09:21AM  Why Galapagos NV Stock Is Soaring Today Motley Fool
08:59AM  Gilead-Galapagos Ink $5.1B Deal for Additional Compounds Zacks
08:33AM  Factbox: The Galapagos drugs pipeline that has drawn in Gilead Reuters
07:00AM  Market Morning: Gilead Moves On Galapagos, Hong Kong Keeps Fighting, Trump Tweets Market Exclusive
05:40AM  Gilead Boosts Investment in Inflammatory Specialist Galapagos by $5.1 Billion
05:30AM  UPDATE 2-Europe closes higher as upbeat China data boosts German shares Reuters
03:16AM  Gilead to Boost Stake in Galapagos as Part of $5.1 Billion Deal Bloomberg
02:35AM  Gilead invests $5 billion to deepen ties with biotech Galapagos Reuters
12:49PM  Gilead invests $5 billion to deepen ties with biotech Galapagos Reuters
Jul-09-19 12:52PM  Here's Why Galapagos NV Stock Rose 13.4% in June Motley Fool
Jul-02-19 09:54AM  Gilead to Submit NDA for Inflammation Drug Filgotinib in '19 Zacks
04:56AM  Galapagos NV (AMS:GLPG): Financial Strength Analysis Simply Wall St.
Jul-01-19 07:10PM  Gilead plans to submit arthritis drug to FDA this year MarketWatch
Jun-23-19 09:46PM  Heres What Hedge Funds Think About Galapagos NV (GLPG) Insider Monkey
Jun-20-19 04:02PM  Galapagos increases share capital through warrant exercises GlobeNewswire
Jun-17-19 04:01PM  Transparency notification GlobeNewswire
Jun-12-19 06:38PM  Galapagos Ends Enrollment in Osteoarthritis Study Before Time Zacks
Jun-11-19 01:01AM  Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis patients GlobeNewswire
04:30PM  Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019) Business Wire
May-28-19 04:02PM  Gilead Gains 6.8% YTD as HIV Franchise Maintains Momentum Zacks
May-22-19 05:51AM  What Kind Of Shareholder Appears On The Galapagos NV's (AMS:GLPG) Shareholder Register? Simply Wall St.
May-19-19 02:00PM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
May-02-19 10:00AM  Better Buy: Vertex Pharmaceuticals vs. Galapagos Motley Fool
Apr-30-19 06:47AM  Will Gilead Stock Get A Needed Boost From This Weeks Earnings Report? InvestorPlace
Apr-26-19 09:46PM  Galapagos NV (GLPG) Q1 2019 Earnings Call Transcript Motley Fool
Apr-25-19 04:02PM  Galapagos reports on historic first quarter 2019 GlobeNewswire
Apr-23-19 04:37PM  Here is What Hedge Funds Really Think About Galapagos NV (GLPG) Insider Monkey
04:02PM  Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients GlobeNewswire
Apr-10-19 05:03PM  Galapagos creates new warrant plans GlobeNewswire
11:25AM  Gilead stock upgraded to buy from neutral at UBS MarketWatch
Apr-09-19 07:46AM  Why Galapagos NV Stock Bolted Higher in March Motley Fool
Apr-08-19 05:25PM  Gilead Files sNDA for Label Expansion of HIV Therapy Descovy Zacks
Mar-31-19 04:04PM  Publication of the annual report and invitation to the annual shareholders' meeting GlobeNewswire
Mar-29-19 04:32PM  Why BlackBerry, Galapagos, and Progress Software Jumped Today Motley Fool +22.52%
03:23PM  Wall Street is buzzing about Gileads rheumatoid arthritis drug. Heres why MarketWatch
11:31AM  Why Galapagos Stock Is Crushing It Today Motley Fool
11:06AM  Galapagos Soars After Rheumatoid Arthritis Drug Meets Primary Endpoint
10:56AM  Gilead Sciences and Galapagos Stock Are Rising on Upbeat Trial Data
07:42AM  The Daily Biotech Pulse: Safety Board Clears Eisai's Alzheimer's Study, Positive Trial Results For Galapagos-Gilead Benzinga
05:04PM  Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients Business Wire
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company's clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, and ulcerative colitis; Phase II trials for small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. Its clinical stage programs also comprise GLPG1690I, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof of concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, the company engages in the development of GLPG1972, which is in the ROCCELLA Phase II trial in osteoarthritis patients; MOR106 that is in Phase I and II trials in atopic dermatitis patients; and GLPG3312, a Toledo molecule, which is in Phase I clinical development for various indications. Galapagos NV has collaboration agreement with Servier for GLPG1972; Les Laboratoires Servier for GLPG1972; MorphoSys AG and Novartis Pharma AG for MOR106; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis; and Evotec for fibrosis, as well as a drug discovery research collaboration agreement with HitGen to identify small molecule leads. The company was founded in 1999 and is headquartered in Mechelen, Belgium.